All episodes

In this plain language podcast, the authors discuss highlights from the American Urological Association (AUA) Annual Meeting 2025. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of bladder cancer. This podcast is intended to broaden the reach of complex data and insights from AUA 2025 to a broader audience, including non-specialists, helping enable better informed treatment decisions between patients and healthcare professionals. The authors introduce the current treatment landscape for patients and discuss four clinical trials focusing on patients with bacillus Calmette-Guérin (BCG)-naïve and BCG-unresponsive high-risk...

Managing prostate cancer today means balancing cancer control with overall health and wellbeing. This episode explores how chronic conditions, frailty, and quality-of-life considerations shape treatment choices from localised to advanced disease. Authors discuss why survival data has shifted the rationale for radical interventions, the complexities introduced by systemic therapy, and why assessing physiological age matters more than chronological age. Discover how comprehensive geriatric assessment supports personalised care, and how holistic, multidisciplinary decision-making can align treatment with life expectancy, patient preference, and independence.

This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the...

In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of prostate cancer. This podcast is intended to broaden the reach of complex data and insights from ASCO 2025 to a broader audience, including non-specialists, helping enable better-informed treatment decisions between patients and healthcare professionals.

This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the...

This podcast is published open access in Pulmonary Therapy and is fully citeable. You can access the original published podcast article through the Pulmonary Therapy website and by using this link: https://link.springer.com/article/10.1007/s41030-025-00330-1. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate...

Real-World Perspectives on Switching Patients With Multiple Sclerosis From Anti-CD20 Therapy to Cladribine Tablets From US-Based Advanced Practice Providers: A Podcast

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-025-03391-5. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as...

A Podcast Discussion on Medical Treatment in R/M-SCCHN in the Year 2025—Standard and Considerations for an Individualized Treatment

In this podcast, speakers Dr Konrad Klinghammer and Dr Philipp Ivanyi discuss the general principles of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), with a focus on key phase 3 clinical trials such as KEYNOTE-048 and EXTREME. The strengths and limitations of these studies are evaluated, and in the context of additional phase 2 trials, considerations are made regarding individualised treatment strategies based on patient-specific characteristics when selecting first-line therapy. Second-line treatment decisions...

Living with Eosinophilic Granulomatosis with Polyangiitis (EGPA): Podcast of a Patient-Physician Discussion

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-025-03400-7. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original...

This podcast is published open access in Dermatology and Therapy and is fully citeable. You can access the original published podcast article through the Dermatology and Therapy website and by using this link:https://link.springer.com/article/10.1007/s13555-025-01551-7. All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and...

Patient and Physician Perspectives on Multiple Myeloma Data Presented at ASCO and EHA 2025: A Podcast

In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed, supplemented with additional reflections from the European Hematology Association (EHA) 2025 Congress. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of multiple myeloma (MM). This podcast is intended to broaden the reach of complex data on MM from these scientific meetings to a broader audience, including nonspecialists, helping enable better informed...

The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast

Dr. Balazs Halmos and Dr. Melissa Johnson present the phase 2b COPERNICUS study evaluating subcutaneous amivantamab, with lazertinib as first-line treatment, or with chemotherapy as second-line treatment for EGFR-mutated non-small cell lung cancer.The intent of this vodcast is to review the study design for COPERNICUS, highlighting how it combines pragmatic elements to assess the efficacy and safety of subcutaneous amivantamab with supportive care for prevention and management of adverse events in a diverse...